Generic name: INSULIN DEGLUDEC 100U in 1mL
Dosage form: injection, solution
Medically reviewed by Drugs.com. Last updated on Nov 21, 2018.
Important Administration Instructions
- Always check insulin labels before administration [see Warnings and Precautions (5.4)].
- Inspect visually for particulate matter and discoloration. Only use TRESIBA if the solution appears clear and colorless.
- Inject TRESIBA subcutaneously into the thigh, upper arm, or abdomen.
- Rotate injection sites within the same region from one injection to the next to reduce the risk of lipodystrophy [see Adverse Reactions (6.1)].
- For pediatric patients requiring less than 5 units of TRESIBA each day, use the TRESIBA U-100 vial.
- Use TRESIBA with caution in patients with visual impairment that may rely on audible clicks to dial their dose.
- DO NOT administer TRESIBA intravenously or in an insulin infusion pump.
- DO NOT dilute or mix TRESIBA with any other insulin products or solutions.
- DO NOT transfer TRESIBA from the TRESIBA pen into a syringe for administration [see Warnings and Precautions (5.4)].
General Dosing Instructions
- TRESIBA is available in 2 concentrations (U-100 and U-200):
- TRESIBA U-100 concentration is available in 2 presentations, FlexTouch pen and vial
- TRESIBA U-100 single-patient-use FlexTouch pen contains 300 units of TRESIBA U-100. It delivers doses in 1 unit increments and can deliver up to 80 units in a single injection.
- TRESIBA U-100 multiple-dose vial contains 1000 units of TRESIBA U-100. Use vial only with a U-100 insulin syringe.
- Tresiba U-200 concentration is only available in a FlexTouch pen
- TRESIBA U-200 single-patient-use FlexTouch pen contains 600 units of TRESIBA U-200. It delivers doses in 2 unit increments and can deliver up to 160 units in a single injection.
- DO NOT perform dose conversion when using the TRESIBA U-100 or U-200 pens. The dose window shows the number of insulin units to be delivered and no conversion is needed.
- In adults, inject TRESIBA subcutaneously once-daily at any time of day.
- In pediatric patients inject TRESIBA subcutaneously once-daily at the same time every day.
- Individualize and titrate the dose of TRESIBA based on the patient’s metabolic needs, blood glucose monitoring results, and glycemic control goal.
- The recommended days between dose increases are 3 to 4 days.
- Dose adjustments may be needed with changes in physical activity, changes in meal patterns (i.e., macronutrient content or timing of food intake), changes in renal or hepatic function or during acute illness to minimize the risk of hypoglycemia or hyperglycemia [see Warnings and Precautions (5.3)].
- For adult patients, instruct patients who miss a dose of TRESIBA to inject their daily dose during waking hours upon discovering the missed dose. Instruct patients to ensure that at least 8 hours have elapsed between consecutive TRESIBA injections.
- For pediatric patients, instruct patients who miss a dose of TRESIBA to contact their healthcare provider for guidance and to monitor blood glucose levels more frequently until the next scheduled TRESIBA dose.
Starting Dose in Insulin Naïve Patients
Type 1 Diabetes Mellitus:
The recommended starting dose of TRESIBA in insulin naïve patients with type 1 diabetes is approximately one-third to one-half of the total daily insulin dose. The remainder of the total daily insulin dose should be administered as a short-acting insulin and divided between each daily meal. As a general rule, 0.2 to 0.4 units of insulin per kilogram of body weight can be used to calculate the initial total daily insulin dose in insulin naïve patients with type 1 diabetes.
Type 2 Diabetes Mellitus:
The recommended starting dose of TRESIBA in insulin naïve patients with type 2 diabetes mellitus is 10 units once daily.
Starting Dose in Patients Already on Insulin Therapy
Adults withType 1 or Type 2 Diabetes Mellitus:
Start TRESIBA at the same unit dose as the total daily long or intermediate-acting insulin unit dose.
Pediatric Patients 1 Year of Age and Older with Type 1 or Type 2 Diabetes Mellitus:
Start TRESIBA at 80% of the total daily long or intermediate-acting insulin unit dose to minimize the risk of hypoglycemia [see Warnings and Precautions (5.2)].
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
- What are the ingredient drugs in Ryzodeg 70/30?
- What is the difference between Soliqua and Xultophy?
- Toujeo vs Tresiba - What's the difference between them?
- How long does Tresiba last without refrigeration?
More about Tresiba (insulin degludec)
- Side Effects
- During Pregnancy
- Drug Interactions
- Support Group
- Pricing & Coupons
- 88 Reviews
- Drug class: insulin
- FDA Alerts (1)
- FDA Approval History